IGF-1 LR3: The Long-Acting Anabolic Growth Factor
Last updated: March 2026
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 engineered with a 13 amino acid N-terminal extension and Arg3 substitution. These modifications eliminate IGFBP binding and triple the circulating half-life, creating a potent anabolic agent that stimulates both muscle cell proliferation and hyperplasia in preclinical research.
🧪 Buy Igf1 Lr3 Guide at Swiss Chems →SubQ Once Daily
vs. Native IGF-1
vs. 70 AA Native
📋 On this page
How IGF-1 LR3 Works
IGF-1 LR3 was engineered to maximize IGF-1 receptor activation by eliminating the serum binding proteins (IGFBPs) that sequester native IGF-1. The result is a growth factor with prolonged receptor exposure and potent downstream anabolic signaling through PI3K/Akt/mTOR and MAPK pathways.
Native IGF-1 circulates ~95% bound to six IGF binding proteins (primarily IGFBP-3 and IGFBP-5), which limit receptor access and shorten effective half-life to 6-10 hours. The Arg3 substitution in IGF-1 LR3 reduces IGFBP affinity ~1000-fold, creating a molecule that remains largely free and biologically active for ~20 hours.
IGF-1 LR3 activates the IGF-1 receptor (IGF-1R) on satellite cells (muscle stem cells), driving both hypertrophy (existing fiber growth) and hyperplasia (new muscle fiber formation). Hyperplasia — the creation of new muscle cells — is the primary differentiator from testosterone or GH alone. Demonstrated in animal models.
IGF-1R activation phosphorylates IRS-1, activating the PI3K/Akt pathway which drives mTORC1, the master regulator of protein synthesis. Simultaneously, the MAPK/ERK pathway promotes cell proliferation. The prolonged half-life of LR3 means these pathways remain activated for hours longer than native IGF-1 stimulation.
IGF-1R shares ~60% structural homology with the insulin receptor, and IGF-1 LR3 activates insulin receptors at sufficient concentrations. This drives glucose uptake and can suppress hepatic glucose output, causing clinically significant hypoglycemia. The extended half-life amplifies this risk compared to short-acting IGF-1 DES.
What the Research Shows
Preclinical animal studies and in vitro data. IGF-1 LR3 is a research reagent used extensively in cell biology; human clinical data is limited.
Side Effects & Risks
Key Takeaways
- ~3× longer half-life than native IGF-1 due to minimal IGFBP binding
- Potent anabolic — drives hyperplasia (new muscle cells) in animal models
- 20-60mcg SubQ is the standard research dose range
- Activates IGF-1R → PI3K/Akt/mTOR → protein synthesis
- Extensively used in cell biology research as a proliferative agent
- Most evidence is preclinical; human RCTs are lacking
- Hypoglycemia is a real, serious risk — have glucose available
- Stimulates growth of all IGF-1R-expressing tissues, not just muscle
- Theoretical tumor promotion risk due to pro-proliferative signaling
- No approved human use; long-term safety data absent
🛒 Recommended Products
Research supplies for IGF-1 LR3 protocols.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and research purposes only. IGF-1 LR3 is not approved for human use. It is a research reagent. Evidence cited is primarily from in vitro cell studies and animal experiments. Hypoglycemia is a serious risk. Consult a qualified physician before any hormone or peptide use.